The Interaction between DNMT1 and High‐Mannose CD133 Maintains the Slow‐Cycling State and Tumorigenic Potential of Glioma Stem Cell
Source abstract
Abstract
Abstract The quiescent/slow‐cycling state preserves the self‐renewal capacity of cancer stem cells (CSCs) and leads to the therapy resistance of CSCs. The mechanisms maintaining CSCs quiescence remain largely unknown. Here, it is demonstrated that lower expression of MAN1A1 in glioma stem cell (GSC) resulted in the formation of high‐mannose type N‐ glycan on CD133. Furthermore, the high‐mannose type N‐ glycan of CD133 is necessary for its interaction with DNMT1. Activation of p21 and p27 by the CD133–DNMT1 interaction maintains the slow‐cycling state of GSC, and promotes chemotherapy resistance and tumorigenesis of GSCs. Elimination of the CD133–DNMT1 interaction by a cell‐penetrating peptide or MAN1A1 overexpression inhibits the tumorigenesis of GSCs and increases the sensitivity of GSCs to temozolomide. Analysis of glioma samples reveals that the levels of high‐mannose type N‐ glycan are correlated with glioma recurrence. Collectively, the high mannose CD133–DNMT1 interaction maintains the slow‐cycling state and tumorigenic potential of GSC, providing a potential strategy to eliminate quiescent GSCs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer Cells and Metastasis · Glioma Diagnosis and Treatment · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
NHC Key Laboratory of Glycoconjuates Research Department of Biochemistry and Molecular Biology School of Basic Medical Sciences Fudan University Shanghai 200032 P. R. China
Department of Neurosurgery Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong 250021 P. R. China
Division of Neurosurgery Zhongshan Hospital Fudan University Shanghai 200032 P. R. China
Funding
National Natural Science Foundation of China
References (73)
Show source-provided references
1. 10.1186/s12943-016-0555-x10.1186/s12943-016-0555-x ↗
2. 10.1038/nature0312810.1038/nature03128 ↗
3. 10.1002/stem.184910.1002/stem.1849 ↗
4. 10.1007/s11033-012-1864-910.1007/s11033-012-1864-9 ↗
5. 10.1016/j.stem.2017.10.00110.1016/j.stem.2017.10.001 ↗
6. 10.1155/2017/561947210.1155/2017/5619472 ↗
7. 10.1038/nm.440910.1038/nm.4409 ↗
8. 10.1016/j.ccr.2013.01.02610.1016/j.ccr.2013.01.026 ↗
9. 10.1016/j.stem.2019.02.01810.1016/j.stem.2019.02.018 ↗
10. 10.1016/j.ccr.2013.04.00810.1016/j.ccr.2013.04.008 ↗
11. 10.1016/j.cell.2011.06.00610.1016/j.cell.2011.06.006 ↗
12. 10.1016/j.stem.2018.03.01110.1016/j.stem.2018.03.011 ↗
13. 10.1016/j.bbrc.2007.01.15910.1016/j.bbrc.2007.01.159 ↗
14. 10.1038/nature0538410.1038/nature05384 ↗
15. 10.1016/j.celrep.2012.09.01610.1016/j.celrep.2012.09.016 ↗
16. 10.1073/pnas.121700211010.1073/pnas.1217002110 ↗
17. 10.1074/jbc.M115.71297610.1074/jbc.M115.712976 ↗
18. 10.1016/j.stem.2020.04.00810.1016/j.stem.2020.04.008 ↗
19. 10.18632/oncotarget.411510.18632/oncotarget.4115 ↗
20. 10.1182/blood.V90.12.501310.1182/blood.V90.12.5013 ↗
21. 10.1182/blood.V90.12.500210.1182/blood.V90.12.5002 ↗
22. 10.1158/0008-5472.CAN-09-182010.1158/0008-5472.CAN-09-1820 ↗
23. 10.1038/416552a10.1038/416552a ↗
24. 10.1016/B978-0-12-387685-0.00006-810.1016/B978-0-12-387685-0.00006-8 ↗
25. 10.1016/j.neo.2016.07.00710.1016/j.neo.2016.07.007 ↗
26. 10.1002/hep.2702610.1002/hep.27026 ↗
27. 10.1016/j.ccr.2009.03.01810.1016/j.ccr.2009.03.018 ↗
28. 10.1002/path.228310.1002/path.2283 ↗
29. 10.1038/s41598-019-39229-810.1038/s41598-019-39229-8 ↗
30. Mohan K. N.
31. 10.1126/science.287.5459.180410.1126/science.287.5459.1804 ↗
32. 10.4161/cc.3.3.71010.4161/cc.3.3.710 ↗
33. 10.1038/nature0761810.1038/nature07618 ↗
34. 10.1101/gad.11.7.84710.1101/gad.11.7.847 ↗
35. 10.1158/1078-0432.CCR-10-149910.1158/1078-0432.CCR-10-1499 ↗
36. 10.1016/j.ccr.2012.04.03610.1016/j.ccr.2012.04.036 ↗
37. 10.1016/j.jhep.2015.11.01110.1016/j.jhep.2015.11.011 ↗
38. 10.1073/pnas.152249111310.1073/pnas.1522491113 ↗
39. 10.1128/MCB.00899-0710.1128/MCB.00899-07 ↗
40. 10.1002/stem.131710.1002/stem.1317 ↗
41. 10.2174/138920101566614061709432010.2174/1389201015666140617094320 ↗
42. 10.1007/s00018-008-8222-z10.1007/s00018-008-8222-z ↗
43. 10.1111/j.1743-7563.2010.01279.x10.1111/j.1743-7563.2010.01279.x ↗
44. Moore N. · J. Oncol. · 2011 · 2011
45. 10.1038/nature0523610.1038/nature05236 ↗
46. 10.3892/etm.2015.267510.3892/etm.2015.2675 ↗
47. 10.1016/j.semcancer.2017.02.01110.1016/j.semcancer.2017.02.011 ↗
48. 10.1007/s12038-016-9624-y10.1007/s12038-016-9624-y ↗
49. 10.1007/s00109-008-0357-810.1007/s00109-008-0357-8 ↗
50. 10.1016/j.cell.2007.01.04910.1016/j.cell.2007.01.049 ↗
51. 10.1016/j.ceb.2011.05.00110.1016/j.ceb.2011.05.001 ↗
52. 10.1073/pnas.191649811710.1073/pnas.1916498117 ↗
53. 10.1152/ajprenal.90340.200810.1152/ajprenal.90340.2008 ↗
54. 10.1016/j.trecan.2016.08.00310.1016/j.trecan.2016.08.003 ↗
55. 10.1074/mcp.M110.00271710.1074/mcp.M110.002717 ↗
56. 10.1074/jbc.M111.26154510.1074/jbc.M111.261545 ↗
57. 10.1074/jbc.M80792020010.1074/jbc.M807920200 ↗
58. 10.1002/cbic.20170000110.1002/cbic.201700001 ↗
59. 10.1007/s10719-008-9217-610.1007/s10719-008-9217-6 ↗
60. 10.1186/s12885-020-6699-510.1186/s12885-020-6699-5 ↗
61. 10.1073/pnas.122147811010.1073/pnas.1221478110 ↗
62. 10.1158/0008-5472.CAN-09-170710.1158/0008-5472.CAN-09-1707 ↗
63. 10.1158/0008-5472.CAN-15-326810.1158/0008-5472.CAN-15-3268 ↗
64. 10.1038/ncomms791010.1038/ncomms7910 ↗
65. 10.1371/journal.pone.001133310.1371/journal.pone.0011333 ↗
66. Jung J. · JCI Insight · 2017
67. 10.1200/JCO.2017.73.011910.1200/JCO.2017.73.0119 ↗
68. 10.1016/j.jhep.2021.06.02510.1016/j.jhep.2021.06.025 ↗
69. 10.1016/j.cmet.2018.06.00610.1016/j.cmet.2018.06.006 ↗
70. 10.1016/j.jim.2009.06.00810.1016/j.jim.2009.06.008 ↗
71. 10.1016/j.ccr.2009.12.02010.1016/j.ccr.2009.12.020 ↗
72. 10.1016/j.ccr.2006.03.03010.1016/j.ccr.2006.03.030 ↗
73. 10.1038/s42003-021-02880-x10.1038/s42003-021-02880-x ↗